Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TrimSpa’s future?

This article was originally published in The Tan Sheet

Executive Summary

Goen Technologies, subsidiary company TrimSpa Inc. and its recently deceased spokesperson, Anna Nicole Smith, were named in a class-action lawsuit alleging false and misleading marketing for the TrimSpa X32 weight-loss supplement. The suit was filed Feb. 5 in the California Superior Court of Los Angeles County. Plaintiffs are asking for unspecified damages, restitution and an injunction preventing TrimSpa from making future weight-loss claims. The class action suit quickly follows Goen Technologies' and related marketers' $1.5 mil. settlement with FTC over allegations of unsubstantiated weight-loss claims (1"The Tan Sheet" Jan. 8, 2007, p. 4). TrimSpa's recent legal trouble in conjunction with Smith's death does not bode well for the future of the brand, according to brand consultant Robert K. Passikoff, Ph.D. Not only does the combination of circumstances deliver "too big a hit" for TrimSpa to recover, but there may also be reverberations across the entire weight-loss supplement category, Passikoff said....

You may also be interested in...

FTC Supplement Settlements Spotlight Bayer, Mark First Hoodia Action

Bayer "went too far" with weight-loss and -control claims for its One-A-Day WeightSmart product and violated a 1991 sanction the product's previous owner agreed to, the Federal Trade Commission said Jan. 4 when it announced a record $3.2 million fine against the consumer healthcare giant

Submitting A Non-COVID-19 Product For FDA Review? Then Take A Seat, It’s Gonna Be Awhile

Top US FDA officials Jeff Shuren and William Maisel said in a 15 April blog post that manufacturers should expect a delay in the review of new product submissions thanks to the pandemic. They noted that the agency also won’t be accepting certain IVD pre-submission requests until next year.

Prescience Point Capital Launches Proxy Fight To Change MiMedx's Board

Prescience Point Capital is trying to reshuffle the board of directors leading regenerative medicine company MiMedx, arguing the company’s current board has destroyed shareholder value. The company's tock is selling for about a third of its potential value, according to Prescience.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts